This is a working overview of Melanocortin receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-02. Anything still debated is marked as such rather than presented as settled.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
| Property | Value | Notes |
|---|---|---|
| Primary receptor family | Melanocortin (MC1 to MC5) | Agonist activity reported at several subtypes |
| Signalling pathway | Gs, adenylyl cyclase, cyclic AMP | Canonical melanocortin signalling route |
| Backbone length | Seven amino acids | Classified as a cyclic heptapeptide |
| Ring closure | Lactam bridge | Constrains conformation and resists peptidases |
| Terminal modifications | Acetylated N-terminus, amidated C-terminus | Reduces breakdown by exopeptidases |
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
== Gas source mass spectrometry == Measurement of natural variations in the abundances of stable isotopes of the same element is normally referred to as stable isotope analysis. This field is of interest because the differences in mass between different isotopes leads to isotope fractionation, causing measurable effects on the isotopic composition of samples, characteristic of their biological or physical history. As a specific example, the hydrogen isotope deuterium (heavy hydrogen) is almost double the mass of the common hydrogen isotope. Water molecules containing the common hydrogen isotope (and the common oxygen isotope, mass 16) have a mass of 18. Water incorporating a deuterium atom has a mass of 19, over 5% heavier. The energy to vaporise the heavy water molecule is higher than that to vaporize the normal water so isotope fractionation occurs during the process of evaporation. Thus a sample of sea water will exhibit a quite detectable isotopic-ratio difference when compared to Antarctic snowfall. Samples must be introduced to the mass spectrometer as pure gases, achieved through combustion, gas chromatographic feeds, or chemical trapping. By comparing the detected isotopic ratios to a measured standard, an accurate determination of the isotopic make up of the sample is obtained. For example, carbon isotope ratios are measured relative to the international standard for C. The C standard is produced from a fossil belemnite found in the Peedee Formation, which is a limestone formed in the Cretaceous period in South Carolina, U.S.A.
The vapor-compression cycle is used in most household refrigerators as well as in many large commercial and industrial refrigeration systems. Figure 1 provides a schematic diagram of the components of a typical vapor-compression refrigeration system. The thermodynamics of the cycle can be analyzed on a diagram as shown in Figure 2. In this cycle, a circulating refrigerant such as a low boiling hydrocarbon or hydrofluorocarbons enters the compressor as a vapour. From point 1 to point 2, the vapor is compressed at constant entropy and exits the compressor as a vapor at a higher temperature, but still below the vapor pressure at that temperature. From point 2 to point 3 and on to point 4, the vapor travels through the condenser which cools the vapour until it starts condensing, and then condenses the vapor into a liquid by removing additional heat at constant pressure and temperature. Between points 4 and 5, the liquid refrigerant goes through the expansion valve (also called a throttle valve) where its pressure abruptly decreases, causing flash evaporation and auto-refrigeration of, typically, less than half of the liquid. That results in a mixture of liquid and vapour at a lower temperature and pressure as shown at point 5. The cold liquid-vapor mixture then travels through the evaporator coil or tubes and is completely vaporized by cooling the warm air (from the space being refrigerated) being blown by a fan across the evaporator coil or tubes. The resulting refrigerant vapour returns to the compressor inlet at point 1 to complete the thermodynamic cycle.
=== Clipfish === Over the centuries, several variants of dried fish have evolved. Stockfish, dried as fresh fish and not salted, is often confused with clipfish, in which the fish is salted before drying. After 2–3 weeks in salt the fish has saltmatured and is transformed from wet salted fish to clipfish through a drying process. The salted fish was earlier dried on rocks (clips) on the foreshore. The production method for clipfish (or bacalhau in Portuguese) was developed by the Portuguese, who first mined salt near the brackish water of Aveiro and brought it to Newfoundland, where cod was available in tremendous quantities. Salting was not economically feasible until the 17th century, when cheap salt from southern Europe became available to the maritime nations of northern Europe. Stockfish is cured in a process called fermentation in which cold-adapted bacteria matures the fish, similar to the maturing process of cheese. Clipfish is processed in a chemical curing process called saltmaturing, similar to the maturing processes of other saltmatured products like Parma ham.
=== Incandescent lamps === 'Black light' incandescent lamps are also made from an incandescent light bulb with a filter coating which absorbs most visible light. Halogen lamps with fused quartz envelopes are used as inexpensive UV light sources in the near UV range, from 400 to 300 nm, in some scientific instruments. Due to its black-body spectrum a filament light bulb is a very inefficient ultraviolet source, emitting only a fraction of a percent of its energy as UV, as explained by the black body spectrum.
Sources: en.wikipedia.org
{\displaystyle {\begin{array}{lll}\Delta G_{\text{bind}}=-RT\ln K_{\text{d}}\\[1.3ex]K_{\text{d}}={\dfrac {[{\text{Ligand}}][{\text{Receptor}}]}{[{\text{Complex}}]}}\\[1.3ex]\Delta G_{\text{bind}}=\Delta G_{\text{desolvation}}+\Delta G_{\text{motion}}+\Delta G_{\text{configuration}}+\Delta G_{\text{interaction}}\end{array}}}
If these viruses each contain an RNA segment with a lethal damage, multiple infection can lead to reactivation providing that at least one undamaged copy of each virus gene is present in the infected cell. This phenomenon is known as "multiplicity reactivation". Multiplicity reactivation has been reported to occur in influenza virus infections after induction of RNA damage by UV-irradiation, and ionizing radiation.
=== Analogues === The closely related medication, methylnaltrexone (N-methylnaltrexone), is used to treat opioid-induced constipation but does not treat addiction as it does not cross the blood–brain barrier. Nalmefene (6-desoxy-6-methylenenaltrexone) is similar to naltrexone and is used for the same purposes as naltrexone. Naltrexone should not be confused with naloxone (N-allylnoroxymorphone), which is used in emergency cases of opioid overdose. Other opioid antagonists related to naltrexone include 6β-naltrexol (6β-hydroxynaltrexone), samidorphan (3-carboxamido-4-hydroxynaltrexone), β-funaltrexamine (naltrexone fumarate methyl ester), nalodeine (N-allylnorcodeine), nalorphine (N-allylnormorphine), and nalbuphine (N-cyclobutylmethyl-14-hydroxydihydronormorphine).
== Pharmacology == The half-life varies in around 8 hours at normal doses. Excretion is 65% through urine, mostly in unmetabolized form, and 28% via feces. Clearance is reduced in people with severe kidney disease. Delafloxacin is more active (lower MIC90) than other quinolones against Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus (MRSA). In contrast to most approved fluoroquinolones, which are zwitterionic, delafloxacin has an anionic character, which results in a 10-fold increase in delafloxacin accumulation in both bacteria and cells at acidic pH. This property is believed to confer to delafloxacin an advantage for the eradication of Staphylococcus aureus in acidic environments, including intracellular infections and biofilms. Given its anti-biofilm activity, delafloxacin is increasingly being considered as a treatment option for hardware-associated infections.
==== Agonist Binding and Channel Activation ==== Upon glutamate binding, these two loops move towards each other, leading to pore opening. The channel opens when two sites are occupied, and increases its current as more binding sites are occupied. This opening allows the influx of sodium (Na⁺) and, depending on subunit composition, calcium (Ca²⁺) ions into the postsynaptic neuron, leading to depolarization and the propagation of excitatory signals. Once open, the channel may undergo rapid desensitization, stopping the current.
Sources: en.wikipedia.org
Table 3. Summary of common single-nucleotide polymorphism mutations within human C3orf52 including their position of occurrence and significance. Single nucleotide polymorphisms were found using variation viewer.
While these remains have been extraordinarily well preserved, the embalming fluids and methods used are unknown. In Europe the ancient practice of artificial preservation had become widespread by about 500 CE. The period of the Middle Ages and the Renaissance is known as the anatomists' period of embalming and is characterized by an increased influence of scientific developments in medicine and the need for bodies for dissection purposes. Early methods used are documented by contemporary physicians such as Peter Forestus (1522–1597) and Ambroise Pare (1510–1590). The first attempts to inject the vascular system were made by Alessandra Giliani, who died in 1326. Various attempts and procedures have been reported by Leonardo da Vinci (1452–1519), Jacobus Berengar (1470–1550), Bartholomeo Eustachius (1520–1574), Reinier de Graaf (1641–1673), Jan Swammerdam (1637–1680), and Frederik Ruysch (1638–1731).
=== Diabetes mellitus === Today, the term "diabetes" most commonly refers to diabetes mellitus. Diabetes mellitus is itself an umbrella term for a number of different diseases involving problems processing sugars that have been consumed (glucose metabolism). Historically, this is the "diabetes" which has been associated with sugary urine (glycosuria).
Strained cyclooctenes and other activated alkenes react with tetrazines in an inverse electron-demand Diels-Alder reaction followed by a retro [4+2] cycloaddition (see figure). Three-membered and four-membered cycloalkenes, due to their high ring strain, also make ideal alkene substrates. Similar to other [4+2] cycloadditions, electron-donating substituents on the dienophile and electron-withdrawing substituents on the diene accelerate the inverse-demand Diels-Alder reaction. The diene, the tetrazine, by virtue of having the additional nitrogens, is a good diene for this reaction. The dienophile, the activated alkene, may often be attached to electron-donating alkyl groups on target molecules, thus making the dienophile more suitable for the reaction.
Sources: en.wikipedia.org
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.
The lactam bridge locks the peptide into a defined shape and makes it harder for peptidases to cut the backbone. Terminal blocking groups add further protection at both ends. Together these features extend the molecule's persistence in circulation compared with linear peptides.
Evidence from animals favors hypothalamic melanocortin circuits, yet direct confirmation in humans is lacking. A peripheral vascular contribution has also been proposed. How receptor binding translates into a reported behavioral effect is still not mapped.
Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.